RTP Mobile Logo
Visiting Professors: Investigator Perspectives on the Management of Soft Tissue Sarcoma
Released December 2019

Featuring one-on-one discussion with Dr Seth Pollack on the strategies employed by a panel of leading clinical investigators in a number of challenging clinical situations in the management of localized and metastatic soft tissue sarcoma. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of soft tissue sarcomas (STS).

    Accounting for less than 1% of all cancers, STS are a heterogeneous collection of diseases representing more than 50 different subtypes that can arise in a variety of anatomic locations. Given their relative rarity, histologic diversity and nonspecific symptoms, the accurate diagnosis of STS can represent a substantial challenge to even seasoned practitioners, and selection of a treatment regimen must be based on several factors, including histology, disease biology and patient preference. The current clinical management of STS is multidisciplinary and includes surgery, radiation therapy chemotherapy and targeted treatments. Many areas of controversy persist within the academic and community settings despite guidelines and consensus statements that aim to assist in making management decisions. To provide clinicians with therapeutic strategies to address the disparate needs of patients with STS, this program features one-on-one discussion with a leading STS investigator on key challenges and controversies in the management of STS.


    • Recognize the histologic diversity of adult STS, and appreciate the importance of appropriate assessment and accurate diagnosis to facilitate optimal treatment and long-term outcomes for patients.
    • Assess the importance of multidisciplinary collaboration in the diagnosis and management of STS, and use this information to guide therapeutic decision-making or tertiary care referrals.
    • Evaluate available clinical trial evidence to discern the role of neoadjuvant and adjuvant therapy in the clinical management of STS.
    • Consider age, histology, extent of disease and other clinical and biologic factors to guide the selection and sequencing of therapy for patients with metastatic undifferentiated pleomorphic sarcoma and leiomyosarcoma.
    • Appraise the potential role of local therapy approaches for oligometastatic STS.
    • Recall new data with investigational agents and strategies demonstrating promising activity in STS.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member/Program Co-Chair

    Seth M Pollack, MD
    Associate Member
    Fred Hutchinson Cancer Research Center
    Clinical Research Division
    Associate Professor
    University of Washington
    Division of Oncology
    Seattle, Washington

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo Inc, Lilly, PureTech Health, Seattle Genetics, Tempus; Contracted Research: EMD Serono Inc, Immune Design, Incyte Corporation, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Merck, Omeros Corporation, Presage Biosciences; Data and Safety Monitoring Board/Committee: GlaxoSmithKline.

    Program Co-Chair

    Brian A Van Tine, MD, PhD
    Medical Oncology
    Associate Professor of Medicine
    Sarcoma Program Director
    Barnes-Jewish Hospital
    Washington University in St Louis
    St Louis, Missouri

    Advisory Committee and Consulting Agreements: Adaptimmune, CytRx Corporation, Daiichi Sankyo Inc, Epizyme, Immune Design, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Merck, Pfizer Inc, TRACON Pharmaceuticals Inc; Speakers Bureau: Adaptimmune, Caris Life Sciences, Janssen Biotech Inc, Lilly; Other Remunerated Activities: Merck, Pfizer Inc, TRACON Pharmaceuticals Inc.

    Project Steering Committee Members

    Mark Agulnik, MD
    Professor of Medicine
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Data and Safety Monitoring Board/Committee: Lilly; Speakers Bureau: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Sanofi Genzyme.

    Kristen Ganjoo, MD
    Associate Professor of Medicine
    Director, Stanford Sarcoma Program
    Stanford Cancer Institute
    Stanford, California

    No relevant conflicts of interest to disclose.

    Suzanne George, MD
    Director, Center for Sarcoma and Bone Oncology
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Deciphera Pharmaceuticals, Exelixis Inc, Lilly; Consulting Agreements: Blueprint Medicines, Daiichi Sankyo Inc, Deciphera Pharmaceuticals; Contracted Research: Blueprint Medicines, Deciphera Pharmaceuticals, Novartis, Pfizer Inc; Expert Testimony: Bayer HealthCare Pharmaceuticals; Ownership Interest: Abbott Laboratories, Allergan.

    Shreyaskumar Patel, MD
    Robert R Herring Distinguished Professor of Medicine
    Center Medical Director, Sarcoma Center
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Daiichi Sankyo Inc, Epizyme, Immune Design; Contracted Research: Blueprint Medicines.

    Richard F Riedel, MD
    Associate Professor, Division of Medical Oncology
    Associate Director, Duke Sarcoma Program
    Member, Duke Cancer Institute
    Duke University Health System
    Durham, North Carolina

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Eisai Inc, EMD Serono Inc, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Consulting Agreement: Lilly; Contracted Research: Aadi Bioscience Inc, Arog Pharmaceuticals Inc, Ignyta Inc, Immune Design, Karyopharm Therapeutics, Lilly, NanoCarrier Co Ltd, Novartis, Oncternal Therapeutics, Plexxikon Inc, Roche Laboratories Inc, SpringWorks Therapeutics, Threshold Pharmaceuticals, TRACON Pharmaceuticals Inc; Ownership Interest (Spouse): Limbguard LLC.

    Victor M Villalobos, MD, PhD
    Assistant Professor of Medicine
    Director, Sarcoma Medical Oncology
    Director, Molecular Oncology Therapeutics Team
    University of Colorado Denver
    Denver, Colorado

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Blueprint Medicines, Janssen Biotech Inc, Lilly, NanoCarrier Co Ltd, Novartis, SpringWorks Therapeutics.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2019
    Expiration date: December 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):